Childhood pheochromocytoma in a survivor of central primitive neuroectodermal tumor

Nakano, Yoshiko; Fujimaru, Rika; Ishii, Keiichi; Sakamoto, Hiroaki; Inoue, Takeshi; Shinoda, Masahiro; Yamada, Hiroshi

doi:10.1111/ped.12074

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mean time from diagnosis of primary to second malignancy was 5 years (range: 2 years 1 month to 10 years 3 months), compared with 2-8 years published elsewhere. [13][14][15][16][17][18][27][28][29]42] These results support the need for close, long-term follow-up of pediatric cancer survivors for late effects.…”

Section: Discussionmentioning

confidence: 76%

“…[1][2][3][4][5][6][7][8][9] Primary neoplasms that are more commonly associated with SMN include leukemia, lymphoma, retinoblastoma, medulloblastoma, craniopharyngioma, and neuroblastoma. [13][14][15][16] Radiation therapy is used therapeutically or preemptively in pediatric malignancies and has been linked with increased survival rates not without late effects. The term radiation-induced malignancy is used to describe malignancies which occur in tissues exposed to radiation that arise from the primary malignancy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Second malignant neoplasms in children and adolescents treated for blood malignancies and solid tumors: A single-center experience of 15 years

Katzilakis

Tsirigotaki

Stratigaki

et al. 2018

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Context: The occurrence of second malignancies is not rare in children treated for primary tumors. Objectives: The aim of this study was to investigate the occurrence and the outcomes of second malignancies in children and adolescents from a large tertiary pediatric hematology-oncology center. Materials and Methods: A retrospective study was performed looking into the characteristics and outcomes of second malignant neoplasms in children and adolescents treated for primary malignancies in a single center over a 15-year period. Results: Among 270 children and adolescents treated for hematological malignancies and solid tumors from 2000 to 2015, five cases of second malignancy were diagnosed including cancer of the parotid gland, renal cell carcinoma, Hodgkin’s lymphoma, thyroid carcinoma, and transitional liver cell carcinoma in patients previously treated for acute myeloid leukemia, glioblastoma multiforme, B-acute lymphoblastic leukemia, Langerhans cell histiocytosis, and medulloblastoma, respectively. Primary malignancies were treated with chemotherapy in all cases and four out of five patients had also received radiotherapy. Mean age at diagnosis of second malignancy was 10 years and 4 months. Overall survival after diagnosis of second malignancy was 80% at 12 months and 75% at 5 years. Conclusions: Close surveillance and long-term follow-up are mandatory for the identification of late effects in children treated for malignancy.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Introductionmentioning

confidence: 99%

Second malignant neoplasms in children and adolescents treated for blood malignancies and solid tumors: A single-center experience of 15 years

Katzilakis

Tsirigotaki

Stratigaki

et al. 2018

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

show abstract

Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review

Gebauer

Higham

Langer³

et al. 2018

Endocrine Reviews

114

View full text Add to dashboard Cite

The number of patients surviving $5 years after initial cancer diagnosis has significantly increased during the last decades due to considerable improvements in the treatment of many cancer entities. A negative consequence of this is that the emergence of long-term sequelae and endocrine disorders account for a high proportion of these. These late effects can occur decades after cancer treatment and affect up to 50% of childhood cancer survivors. Multiple predisposing factors for endocrine late effects have been identified, including radiation, sex, and age at the time of diagnosis. A systematic literature search has been conducted using the PubMed database to offer a detailed overview of the spectrum of late endocrine disorders following oncological treatment. Most data are based on late effects of treatment in former childhood cancer patients for whom specific guidelines and recommendations already exist, whereas current knowledge concerning late effects in adult-onset cancer survivors is much less clear. Endocrine sequelae of cancer therapy include functional alterations in hypothalamic-pituitary, thyroid, parathyroid, adrenal, and gonadal regulation as well as bone and metabolic complications. Surgery, radiotherapy, chemotherapy, and immunotherapy all contribute to these sequelae. Following irradiation, endocrine organs such as the thyroid are also at risk for subsequent malignancies. Although diagnosis and management of functional and neoplastic long-term consequences of cancer therapy are comparable to other causes of endocrine disorders, cancer survivors need individually structured follow-up care in specialized surveillance centers to improve care for this rapidly growing group of patients.

show abstract

Childhood pheochromocytoma in a survivor of central primitive neuroectodermal tumor

Cited by 2 publications

References 8 publications

Second malignant neoplasms in children and adolescents treated for blood malignancies and solid tumors: A single-center experience of 15 years

Second malignant neoplasms in children and adolescents treated for blood malignancies and solid tumors: A single-center experience of 15 years

Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review

Contact Info

Product

Resources

About